301230.SHE PharmaResources (Shanghai) Co. Ltd. A

The Graham number of PharmaResources (Shanghai) Co. Ltd. A cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

No fundamental analysis for PharmaResources (Shanghai) Co. Ltd. A yet.

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturing organization (CDMO), and commercial manufacturing services for small molecule …

2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.

PharmaResources (Shanghai) Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)

Dividend yield

0.97%

Forward dividend

0.33 CNY

Payout ratio

157.6%

Ex-dividend date

Jul 16, 2026

From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.

Last stock split: 1.3:1 on Jul 16, 2026.

Company name

PharmaResources (Shanghai) Co. Ltd. A

Ticker

301230.SHE

ISIN

CNE1000065Q9

Exchange

Shenzhen Stock Exchange

Sector

Healthcare

Industry

Biotechnology

Employees

1,155

Fiscal year end

December

Address

Building 12, Shanghai, China, 201201

Phone

86 21 5072 0228

Website

pharmaresources.cn

About PharmaResources (Shanghai) Co. Ltd. A

PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturing organization (CDMO), and commercial manufacturing services for small molecule drugs. It is also involved in the research, development, and customized/commercial production of active pharmaceutical ingredients and key intermediates, including ticagrelor, oxiracetam, l-carnitine, velpatasvir, peramivir trihydrate, huperzine A, and vitamin K2, as well as design, screening, and optimization of hit compounds and lead compounds; conducting of structural improvements; and provision of preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights. In addition, the company provides medicinal chemistry, process research and development, pharmaceutical research, molecular building blocks, and pharmacokinetics services. Further, it engages in pharmaceutical technology research and development activities. PharmaResources (Shanghai) Co., Ltd. was founded in 2007 and is based in Shanghai, China.

• Dr. Ping Chen Ph.D.Co-Founder, GM & Chairman · born 1958
• Mr. Rongchang AnFounder & Director · born 1965
• Mr. Shicheng LiFinancial Manager & Accounting Supervisor · born 1977
• Mr. Weicai ZhenDeputy General Manager · born 1962
• Mr. Haifeng LiDeputy General Manager · born 1975